Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Difterivaccin SSI
- Development stage
- Unknown
- Lead developer
- Statens Serum Institut
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Difterivaccin SSI (also known as Difterivaccine SSI) is a monovalent diphtheria toxoid vaccine originally developed and manufactured by the Statens Serum Institut (SSI), a Danish public health institution, and later produced by AJ Vaccines. It contains purified diphtheria toxoid adsorbed to aluminum hydroxide as an adjuvant. The vaccine is indicated for active immunization (both primary vaccination and booster/revaccination) against diphtheria in children and adults. In clinical research, Difterivaccin SSI has been evaluated in Phase 4 trials (such as those sponsored by Örebro Läns Landsting in Sweden) to study re-immunization strategies and protective antibody levels in patients who have lost vaccine-acquired immunity following autologous or allogeneic hematopoietic stem cell transplantation.
- Brand names
- Difterivaccin SSIDifterivaccine SSI
- Other names
- Difterivaccin 'SSI'Difterivaccine 'SSI'Difteri SSI
02
Targets
EEF2 (Eukaryotic elongation factor 2)Diphtheria toxinHBEGF (Heparin-binding EGF-like growth factor)
Beyond the preview
Go deeper on Difterivaccin SSI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Difterivaccin SSI.